Pertuzumab (P) plus high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression after radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC): Primary efficacy analysis results from the phase II PATRICIA study Lin, N. U., Kumthekar, P., Sahebjam, S., Ibrahim, N., Fung, A., Cheng, A., Nicholas, A., Wang, B., Pegram, M. AMER ASSOC CANCER RESEARCH. 2020

View details for DOI 10.1158/1538-7445.SABCS19-P1-18-03

View details for Web of Science ID 000527012500291